Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 601–700 of 1,001

Nano and Microtechnologies for the Delivery of Oligonucleotides with Gene Silencing Properties
Rosa, G. D., & Rotonda, M. I. L. (2009) · Molecules · doi:10.3390/molecules14082801 · Cited by 44
“HO E Helper lipid used in the formulation of cationic liposomes, LPDs, SNALPs and HVJ liposomes [16,18, 20,27,33,36,47-49,50-53,55-57]”
BackgroundMethodResultInfluential
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?
Subramanya, S., Kim, S. S., Manjunath, N., & Shankar, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903448158 · Cited by 47
“For example cationic PEGylated liposomes called ‘stable nucleic acid lipid particles’ (SNAL Ps) have been used to deliver siRNA to the liver in cynomologous monkeys to reduce serum cholesterol and LDL levels [71].”
Background
Optimization of siRNA delivery to target sites: issues and future directions
Khalil, I. A., Yamada, Y., & Harashima, H. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1520836 · Cited by 48
MEF2C Silencing Attenuates Load-Induced Left Ventricular Hypertrophy by Modulating mTOR/S6K Pathway in Mice
Pereira, A. H. M., Clemente, C. F. M. Z., Cardoso, A. C., Theizen, T. H., Rocco, S. A., Judice, C. C., Guido, M. C., Pascoal, V., Lopes‐Cendes, Í., Matos‐Souza, J. R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008472 · Cited by 46
“Such a prolonged effect of systemically delivered siRNA was previously observed for distinct targets in various tissues[19,28], although the underlying mechanism remains unclear.”
Background
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA
Tam, Y. Y. C., Chen, S., Zaifman, J., Tam, Y. K., Lin, P. J. C., Ansell, S., Roberge, M., Ciufolini, M. A., & Cullis, P. R. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.006 · Cited by 44
Topical matrix-based siRNA silences local gene expression in a murine wound model
Thanik, V. D., Greives, M. R., Lerman, O. Z., Seiser, N., Dec, W., Chang, C., Warren, S. M., Levine, J. P., & Saadeh, P. B. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302986 · Cited by 44
mRNA knockdown by single strand RNA is improved by chemical modifications
Haringsma, H. J., Li, J., Soriano, F., Kenski, D. M., Flanagan, W. M., & Willingham, A. T. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1301 · Cited by 45
Nanoparticles for human liver-specific drug and gene delivery systems:in vitroandin vivoadvances
Kasuya, T., & Kuroda, S. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802622096 · Cited by 44
“Although SNALP (stable nucleic acid lipid particles) – cationic liposomes encapsulating siRNA without any targeting mechanism – showed great gene silencing effect in the liver [47] , new liver-specific NP-based medicines should generally harbor an in vivo targeting mechanism.”
Background
Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra, M., Kandalam, M., Rangasamy, J., Shankar, B., Maheswari, U. K., Swaminathan, S., & Krishnakumar, S. (2013) · Europe PMC (PubMed Central) · Cited by 44
Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics
Gindy, M. E., Leone, A. M., & Cunningham, J. J. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.642363 · Cited by 43
“[47] used the technique to generate LNPs encapsulating siRNA (SNALPs).”
Method
Efficient suppression of murine intracellular adhesion molecule-1 using ultrasound-responsive and mannose-modified lipoplexes inhibits acute hepatic inflammation
Un, K., Kawakami, S., Yoshida, M., Higuchi, Y., Suzuki, R., Maruyama, K., Yamashita, F., & Hashida, M. (2012) · Hepatology · doi:10.1002/hep.25607 · Cited by 43
“This dose of siRNA is lower than those reported for other studies evaluating the therapeutic effects using siRNA, although the therapeutic mechanism and delivery methods of each siRNA are likely to be different.(37-39) These findings suggest that the increased distribution of siRNA into HECs by mannose modification (F…”
Result
Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy
Lee, J., Saw, P. E., Gujrati, V., Lee, Y., Kim, H., Kang, S., Choi, M., Kim, J.-I., & Jon, S. (2015) · Theranostics · doi:10.7150/thno.13657 · Cited by 43
“livery platforms for therapeutic siRNA in hepatic diseases,[12-14] as these nanoparticles tend to preferentially localize to the liver upon systemic administration.”
Background
Lyophilisation and concentration of chitosan/siRNA polyplexes: Influence of buffer composition, oligonucleotide sequence, and hyaluronic acid coating
Veilleux, D., Panicker, R. K. G., Chevrier, A., Biniecki, K., Lavertu, M., & Buschmann, M. D. (2017) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2017.09.084 · Cited by 43
Sustained and targeted delivery of siRNA/DP7‐C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy
Zhao, B., Zhou, B., Shi, K. Y., Zhang, R., Dong, C., Xie, D., Tang, L., Tian, Y., Qian, Z., & Li, Y. (2021) · Cancer Science · doi:10.1111/cas.14903 · Cited by 43
The emerging potential of siRNA nanotherapeutics in treatment of arthritis
Kumari, A., Kaur, A., & Aggarwal, G. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100845 · Cited by 46
“Additionally, a single systemic dosage (2.5 mg/kg) of an Apolipoprotein B (ApoB) specific siRNA loaded in SNALPs demonstrated more than 90% silencing impact of ApoB mRNA in cynomolgus monkey’s liver [61] .”
BackgroundInfluential
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
Viegas, C., Patrício, A. B., Prata, J., Fonseca, L., Macedo, A. S., Duarte, S. O. D., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092363 · Cited by 45
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies
Schneider, B., Grote, M., John, M., Haas, A. K., Bramlage, B., lckenstein, L. M., Jahn‐Hofmann, K., Bauss, F., Cheng, W., Croasdale, R., et al. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.39 · Cited by 42
High-density lipoproteins for the systemic delivery of short interfering RNA
McMahon, K. M., & Thaxton, C. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866089 · Cited by 42
“reported success in reducing apoB production from hepatocytes in nonhuman primates resulting in a reduction in serum cholesterol and LDL levels [54].”
Background
Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo
Foster, D. J., Barros, S. A., Duncan, R., Shaikh, S., Cantley, W. L., Dell, A., Bulgakova, E., O′Shea, J., Taneja, N., Kuchimanchi, S., et al. (2012) · RNA · doi:10.1261/rna.031120.111 · Cited by 42
“Duration is best evaluated at doses that result in linear and robust silencing at early times (Zimmermann et al. 2006; Frank-Kamenetsky et al. 2008).”
Background
Neutralized Nanoparticle Composed of SS‐Cleavable and pH‐Activated Lipid‐Like Material as a Long‐Lasting and Liver‐Specific Gene Delivery System
Ukawa, M., Akita, H., Hayashi, Y., Ishiba, R., Tange, K., Arai, M., Kubo, K., Higuchi, Y., Shimizu, K., Konishi, S., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300629 · Cited by 45
Light-Triggered RNA Release and Induction of Hmsc Osteogenesis Via Photodegradable, Dual-Crosslinked Hydrogels
Huynh, C. T., Nguyen, M. K., Naris, M., Tonga, G. Y., Rotello, V. M., & Alsberg, E. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0088 · Cited by 42
Regulation of Interleukin-10 Gene Expression in Macrophages Engulfing Apoptotic Cells
Zhang, Y., Kim, H.-J., Yamamoto, S., Kang, X., & Ma, X. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0004 · Cited by 42
Design of peptide-targeted liposomes containing nucleic acids
Santos, A. O., Gomes-da-Silva, L. C., Bimbo, L. M., de Lima, M. C. P., Simões, S., & Moreira, J. N. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.12.001 · Cited by 41
Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study
Tao, Y., Han, J., & Dou, H. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm31675g · Cited by 42
Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes
Hayashi, Y., Suemitsu, E., Kajimoto, K., Sato, Y., Akhter, A., Sakurai, Y., Hatakeyama, H., Hyodo, M., Kaji, N., Baba, Y., et al. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.4 · Cited by 40
“15–19 Most of these studies focused on a generation of new therapeutic applications, namely, Nanomedicine; however, the siRNA delivery technology would be more beneficial, in particular, in the early stage of drug discovery, in that it can essentially speed up the target selection via a combination…”
Overcoming obstacles to develop effective and safe siRNA therapeutics
Li, L., & Shen, Y. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902911420 · Cited by 41
“Among these, the SNALP receives the most attention due to several high profile publications from Protiva and Alnylam [38,39].”
BackgroundInfluential
siRNA and Cancer Immunotherapy
Ghafouri‐Fard, S., & Ghafouri-Fard, S. (2012) · Immunotherapy · doi:10.2217/imt.12.87 · Cited by 42
siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs
Hajeri, P. B., & Singh, S. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.001 · Cited by 42
Opportunities for treating chronic hepatitis B and C virus infection using RNA interference
Arbuthnot, P. B., Longshaw, V. M., Naidoo, T., & Weinberg, M. S. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00818.x · Cited by 41
Maternal depletion of NLRP5 blocks early embryogenesis in rhesus macaque monkeys (Macaca mulatta)
Wu, X. (2008) · Human Reproduction · doi:10.1093/humrep/den403 · Cited by 40
“Recently, a systemically delivered siRNA was reported to suppress apolipoprotein B (ApoB) gene expression in rhesus macaques for up to 11 days (Zimmermann et al., 2006).”
Background
Cationic lipid nanodisks as an siRNA delivery vehicle
Ghosh, M., Ren, G., Simonsen, J. B., & Ryan, R. O. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0027 · Cited by 40
“The potential therapeutic utility of RNA interference can be seen by the fact that siRNA-mediated silencing of validated disease targets has been shown to improve outcomes in disease models (Hu-Lieskovan et al. 2005; Landen et al. 2005; Zimmermann et al. 2006).”
Biomaterials in RNAi therapeutics: quo vadis?
Wagner, E. (2013) · Biomaterials Science · doi:10.1039/c3bm60071h · Cited by 40
Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy
Omar, R., Yang, J., Liu, H., Davies, N. M., & Gong, Y. (2016) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2016_6 · Cited by 40
Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy
Romano, G., & Kwong, L. N. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9716-7 · Cited by 39
“fact shown promising results both in clinical (NCT01437059) and pre-clinical [43] settings for siRNA delivery, where significant inflammatory response or acute general toxicity were”
Result
Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs
Liu, F., Wang, C., Gao, Y., Li, X., Tian, F., Zhang, Y., Fu, M., Li, P., Wang, Y., & Wang, F. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0338-8 · Cited by 42
In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors
Sasayama, Y., Hasegawa, M., Taguchi, E., Kubota, K., Kuboyama, T., Naoi, T., Yabuuchi, H., Shimai, N., Asano, M., Tokunaga, A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.004 · Cited by 40
Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic
Ali, M. S., Hooshmand, N., El‐Sayed, M. A., & Labouta, H. I. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00732 · Cited by 40
Therapeutic application of RNA interference for hepatitis C virus
Watanabe, T., Umehara, T., & Kohara, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.022 · Cited by 41
Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs
OBRIEN, L. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.11.007 · Cited by 41
Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
Issa, H., Swart, L. E., Rasouli, M., Ashtiani, M., Nakjang, S., Jyotsana, N., Schuschel, K., Heuser, M., Blair, H., & Heidenreich, O. T. (2023) · Leukemia · doi:10.1038/s41375-023-01854-8 · Cited by 38
RNA interference in pain research
Röhl, T., & Kurreck, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04082.x · Cited by 39
Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics
Akhtar, S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.518611 · Cited by 40
Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles
Vader, P., Crielaard, B. J., van Dommelen, S. M., van der Meel, R., Storm, G., & Schiffelers, R. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.080 · Cited by 39
Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase
Li, X., Knight, J. L., Fargue, S., Buchalski, B., Guan, Z., Inscho, E. W., Liebow, A., Fitzgerald, K. J., Querbes, W., Lowther, W. T., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.001 · Cited by 39
Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes
Singh, Y., Tomar, S., Khan, S. A., Meher, J. G., Pawar, V. K., Raval, K., Sharma, K., Singh, P. K., Chaurasia, M., Reddy, B. S., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.050 · Cited by 39
Endosomolytic Bioreducible Poly(amido amine disulfide) Polymer Conjugates for the in Vivo Systemic Delivery of siRNA Therapeutics
Parmar, R. G., Busuek, M., Walsh, E. S., Leander, K. R., Howell, B. J., Sepp‐Lorenzino, L., Kemp, E. A., Crocker, L. S., Leone, A. M., Kochansky, C. J., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300600a · Cited by 39
An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing
Bieńk, K., Hvam, M. L., Pakula, M. M., Dagnæs‐Hansen, F., Wengel, J., Malle, B. M., Kragh‐Hansen, U., Cameron, J., Bukrinski, J. T., & Howard, K. A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.013 · Cited by 39
“Factor VII (FVII) demonstrated in rodent and non-human primates using lipidoid-based nanoparticles [6, 7] and stable nucleic acid lipid particles (SNALPS) [8], respectively.”
Background
Prevention of neointimal formation using miRNA-126-containing nanoparticle-conjugated stents in a rabbit model
Izuhara, M., Kuwabara, Y., Saito, N., Yamamoto, E., Hakuno, D., Nakashima, Y., Horie, T., Baba, O., Nishiga, M., Nakao, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172798 · Cited by 39
“[20,21], there is still the possibility of undesirable side-effects.”
Background
Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery
Leber, N., Nuhn, L., & Zentel, R. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700092 · Cited by 40
Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy
Saw, P. E., Zhang, A., Nie, Y., Zhang, L., Xu, Y., & Xu, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01194 · Cited by 39
Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
“DLinDMA 1,2-dilinoleyloxy-N,Ndimethyl-3aminopropane [52,56]”
BackgroundInfluential
Versatile cationic lipids for siRNA delivery
Sparks, J., Slobodkin, G., Matar, M. M., Congo, R., Ulkoski, D., Rea-Ramsey, A., Pence, C., Rice, J. S., McClure, D., Polach, K. J., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.006 · Cited by 39
MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines
Antonellis, P. D., Liguori, L., Falanga, A., Carotenuto, M., Ferrucci, V., Andolfo, I., Marinaro, F., Scognamiglio, I., Virgilio, A., Rosa, G. D., et al. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0837-4 · Cited by 39
Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases
Kurakula, H., Vaishnavi, S., Sharif, M. Y., & Ellipilli, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c01703 · Cited by 41
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45
“128 Unfortunately, the tolerability of this formulation in the clinic was not sufficient to warrant clinical development.”
Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases
Luck, M. E., Muljo, S. A., & Collins, C. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403146 · Cited by 39
DNAzyme Delivery Systems: Getting Past First Base
Tan, M. L., Choong, P., & Dass, C. R. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902751605 · Cited by 38
“In addition, only a low concentration of 500 ng Dz13 was required for in vivo applications, as compared to the mg/kg doses required for a similar RNA construct – siRNA – to be potent [44] .”
Background
Separation of small interfering RNA stereoisomers using reversed-phase ion-pairing chromatography
Li, L., Leone, T., Foley, J. P., & Welch, C. J. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.04.008 · Cited by 38
Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine
Yamada, Y., Sato, Y., Nakamura, T., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.007 · Cited by 41
ApoB siRNA‐induced Liver Steatosis is Resistant to Clearance by the Loss of Fatty Acid Transport Protein 5 (Fatp5)
Ason, B. L., Castro‐Perez, J. M., Tep, S., Stefanni, A. C., Tadin‐Strapps, M., Roddy, T. P., Hankemeier, T., Hubbard, B. K., Sachs, A. B., Flanagan, W. M., et al. (2011) · Lipids · doi:10.1007/s11745-011-3596-3 · Cited by 38
“Both antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting ApoB reduce LDL-c in mice and in non-human primates [14–18].”
Background
RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment
Spizzo, R., Rushworth, D., Guerrero, M., & Calin, G. A. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.030 · Cited by 38
MicroRNA Interference Technologies
Wang, Z. (2009) · Springer eBooks · doi:10.1007/978-3-642-00489-6 · Cited by 37
Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles
Lee, D. S., Amirthalingam, S., Lee, C., Rajendran, A. K., Ahn, Y.-H., & Hwang, N. S.-Y. (2023) · Nanoscale Advances · doi:10.1039/d3na00198a · Cited by 40
Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design
Yan, J., Zhang, H., Li, G., Su, J., Wei, Y., & Xu, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.012 · Cited by 40
“4B) 57 .”
Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo
Creusat, G., Thomann, J., Maglott, A., Pons, B., Dontenwill, M., Guérin, É., Frisch, B., & Zuber, G. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.007 · Cited by 37
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis
Clark, K. L., Hughes, S. A., Bulsara, P. A., Coates, J., Moores, K., Parry, J. D., Carr, M., Mayer, R. J., Wilson, P. A., Gruenloh, C., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.57 · Cited by 37
Chaperonin–Dendrimer Conjugates for siRNA Delivery
Nussbaumer, M. G., Duskey, J. T., Röther, M., Renggli, K., Chami, M., & Bruns, N. (2016) · Advanced Science · doi:10.1002/advs.201600046 · Cited by 38
5′-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger
Kumar, P., Parmar, R. G., Brown, C. R., Willoughby, J. L. S., Foster, D. J., Babu, I. R., Schofield, S., Jadhav, V., Charissé, K., Nair, J. K., et al. (2019) · Chemical Communications · doi:10.1039/c9cc00977a · Cited by 37
Galactose engineered nanocarriers: Hopes and hypes in cancer therapy
Fatima, M., Karwasra, R., Almalki, W. H., Sahebkar, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111759 · Cited by 37
Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics
Lehofer, B., Bloder, F., Jain, P., Marsh, L. M., Leitinger, G., Olschewski, H., Leber, R., Olschewski, A., & Prassl, R. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.10.009 · Cited by 36
Peptide- and polymer-based delivery of therapeutic RNA
Fröhlich, T., & Wagner, E. (2009) · Soft Matter · doi:10.1039/b916053a · Cited by 37
Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation
Guo, B., Zhang, B., Zheng, L., Tang, T., Liu, J., Wu, H., Yang, Z., Peng, S., He, X., Zhang, H., et al. (2013) · Bone · doi:10.1016/j.bone.2013.11.007 · Cited by 36
Development of a multifunctional envelope-type nano device and its application to nanomedicine
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.042 · Cited by 37
The Targeting of Native Proteins to the Endoplasmic Reticulum-Associated Degradation (ERAD) Pathway: An Expanding Repertoire of Regulated Substrates
Kumari, D., & Brodsky, J. L. (2021) · Biomolecules · doi:10.3390/biom11081185 · Cited by 34
Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts
Snyder, L. L., Esser, J. M., Pachuk, C. J., & Steel, L. F. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.04.001 · Cited by 36
Developing Lipid Nanoparticle-Based siRNA Therapeutics for Hepatocellular Carcinoma Using an Integrated Approach
Li, L., Wang, R., Wilcox, D. M., Sarthy, A. V., Lin, X., Huang, X., Tian, L., Dande, P., Hubbard, R. D., Hansen, T. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0983-t · Cited by 36
“Lipid nanoparticle formulation SNALP was prepared according to the literaturedescribed procedure (7).”
Method
Assessing the Heterogeneity Level in Lipid Nanoparticles for siRNA Delivery: Size-Based Separation, Compositional Heterogeneity, and Impact on Bioperformance
Zhang, J., Pei, Y., Zhang, H., Wang, L., Arrington, L., Zhang, Y., Glass, A., & Leone, A. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3005337 · Cited by 36
Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma
Arbuthnot, P. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1670 · Cited by 36
Oligonucleotide delivery: a patent review (2010 – 2013)
Grijalvo, S., Aviñó, A. M., & Eritja, R. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.915944 · Cited by 35
“The therapeutic effects of some SLNPs in RNAi or antisense technology have been reported in multiple in vivo experiments and clinical trials for hypercholesterolemia, TTR, solid tumors or cancer treatments (Table 1) being systemic administration the most preferred application for these delivery platforms [25,26].”
Background
RNA Interference as Therapeutics for Hepatocellular Carcinoma
Xu, C., Lee, S. A., & Chen, X. (2010) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489211793980097 · Cited by 36
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Cationic siRNAs Provide Carrier-Free Gene Silencing in Animal Cells
Nothisen, M., Kotera, M., Voirin, É., Rémy, J.-S., & Behr, J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja908017e · Cited by 35
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis
Zhou, L., & Hussain, M. M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309247 · Cited by 35
c-Jun knockdown sensitizes osteosarcoma to doxorubicin
Dass, C. R., Khachigian, L. M., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0086 · Cited by 34
Development of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
Infrared multiphoton dissociation of small-interfering RNA anions and cations
Gardner, M. W., Li, N., Ellington, A. D., & Brodbelt, J. S. (2010) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2009.12.011 · Cited by 34
“011 nary artery disease [8], Alzheimer’s disease [9], and HIV [10, 11].”
Background
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
Synthesis, Cell-Surface Binding, and Cellular Uptake of Fluorescently Labeled Glucose−DNA Conjugates with Different Carbohydrate Presentation
Ugarte‐Uribe, B., Pérez‐Rentero, S., Lucas, R., Aviñó, A. M., Reina, J. J., Alkorta, I., Eritja, R., & Morales, J. C. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100079n · Cited by 34
Delivery of RNAi therapeutics: work in progress
Miller, A. D. (2013) · Expert Review of Medical Devices · doi:10.1586/17434440.2013.855471 · Cited by 34
siRNAs: their potential as therapeutic agents – Part II. Methods of delivery
Singh, S. K., & Hajeri, P. B. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.002 · Cited by 34
An ESI-MS method for characterization of native and modified oligonucleotides used for RNA interference and other biological applications
Shah, S., & Friedman, S. H. (2008) · Nature Protocols · doi:10.1038/nprot.2007.535 · Cited by 34
Interfering RNA and HIV: Reciprocal Interferences
Corbeau, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000162 · Cited by 34
“The fact that siRNAs or siRNAs antagonists modified chemically for stability and conjugated to cholesterol or liposomes have a specific, long-lasting, and ubiquitous effect when administrated intravenously [47,48] is particularly encouraging for this kind of approach.”
Background
Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer
Durand, N., Borgés, S., & Störz, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2011-2 · Cited by 33
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
Niemietz, C., Chandhok, G., & Schmidt, H. (2015) · Molecules · doi:10.3390/molecules201017944 · Cited by 34
“Currently, therapeutic oligonucleotides are subjected to clinical trials for prevention of various liver disease [11,87,127].”
Background
Synergistic effects of surfactants and sugars on lipoplex stability during freeze-drying and rehydration
Yu, J., & Anchordoquy, T. J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21564 · Cited by 33
Novel pharmacotherapies for cardiac amyloidosis
Alexander, K. M., Singh, A., & Falk, R. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.011 · Cited by 33
“Lipid nanoparticles have been shown to be very effective in delivering siRNAs to hepatocytes (Akinc et al., 2010; Zimmermann et al., 2006).”
Therapeutic strategies for acute intermittent porphyria
Zhao, L., Wang, X., Zhang, X., Liu, X., Ma, N., Zhang, Y., & Zhang, S. (2020) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2020.03089 · Cited by 36
Lipid and Peptide-Oligonucleotide Conjugates for Therapeutic Purposes: From Simple Hybrids to Complex Multifunctional Assemblies
Fàbrega, C., Aviñó, A. M., Navarro, N., Jorge, A. F., Grijalvo, S., & Eritja, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020320 · Cited by 34
“Stable nucleic acid lipid nanoparticles (SNALP) and solid-lipid nanoparticles (SLN) were developed for the delivery of siRNAs [56,57] showing for the first time the in vivo inhibition of ApoB in non-human primates [56].”
Background
Antisense apolipoprotein B therapy: where do we stand?
Akdim, F., Stroes, E. S. G., & Kastelein, J. J. P. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328248b4ad · Cited by 33

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks